A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29386624.
- Also identified by DOI 10.1038/s41467-018-02851-7 and PMC identifier 5792646.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Previously we have reported that metastatic melanoma cell lines and tumor specimens have reduced expression of ADAR1 and consequently are impaired in their ability to perform A-to-I microRNA (miRNA) editing. The effects of A-to-I miRNAs editing on melanoma growth and metastasis are yet to be determined. Here we report that miR-378a-3p is undergoing A-to-I editing only in the non-metastatic but not in metastatic melanoma cells. The function of the edited form is different from its wild-type counterpart. The edited form of miR-378a-3p preferentially binds to the 3'-UTR of the PARVA oncogene and inhibits its expression, thus preventing the progression of melanoma towards the malignant phenotype. Indeed, edited miR-378a-3p but not its WT form inhibits melanoma metastasis in vivo. These results further emphasize the role of RNA editing in melanoma progression.
Medical subject headings
- Adenosine
- Gene Expression Regulation, Neoplastic
- Inosine
- Melanoma
- MicroRNAs
- Microfilament Proteins
- RNA Editing
- Skin Neoplasms